Category: Patent Profiles

    By Donald Zuhn — Last week, CellCyte Genetics announced that it had been granted U.S. Patent No. 7,282,222, which relates to methods for delivering stem cells to a target tissue in a mammal using glycoconjugate to traffic the cells to a desired organ.  According to CellCyte’s press release, the Kirkland, Washington based biotech…

    By Christopher P. Singer — Nventa Biopharmaceuticals Corporation announced on October 29, 2007 that U.S. Patent 7,262,014, titled "Immune responses against HPV antigens elicited by compositions comprising an HPV antigen and a stress protein or an expression vector capable of expression of these proteins" has been granted by the U.S. Patent and Trademark…

    By Donald Zuhn — Ryogen LLC announced today that it had been granted U.S. Patent No. 7,273,718.  The ‘718 patent, which relates to an isolated genomic polynucleotide fragment that encodes human soluble (cytosolic) aminopeptidase P, appears to be the Suffern, New York-based genomics company’s second U.S. patent.  According to Ryogen’s website, the company,…

    By Suresh Pillai — Epigenomics AG of Frankfurt, Germany has been awarded U.S. Patent No. 7,229,759 ("Highly sensitive method for the detection of cytosine methylation patterns," issued June 12, 2007).  The ‘759 patent, covering a method for the detection of cytosine methylation in genomic DNA samples, is the fourteenth U.S. patent to be…

    By Sherri Oslick — Immunomedics, Inc. of Morris Plains, NJ has been awarded U.S. Patent No. 7,282,567 ("Monoclonal antibody hPAM4," issued October 16, 2007) covering a humanized monoclonal antibody to a particular epitope in the MUC1 antigen expressed in most pancreatic cancers.  The patent also covers therapeutic and diagnostic derivatives of hPAM4 for…

    By Donald Zuhn — Last week, MorphoSys AG announced that it had been granted U.S. Patent No. 7,264,963.  The ‘963 patent, which relates to the preparation of a library of human-derived antibody genes by the use of synthetic consensus sequences that cover the structural repertoire of antibodies encoded in the human genome, is…

    By Donald Zuhn — Earlier this month, CODA Genomics, Inc. announced that it had been granted U.S. Patent No. 7,262,031.  CODA Genomics, Inc., which derives its name from its Computational Optimized DNA Assembly technology, has exclusively licensed the ‘031 patent from the University of California, Irvine (UCI) Office of Technology Assessment (OTA).  The…

    By Donald Zuhn — On Tuesday, ARIUS Research Inc. announced that it had been granted U.S. Patent Nos. 7,256,271 and 7,256,272.  According to the statement released by ARIUS, the ‘271 patent relates to a CEA targeting antibody having demonstrated potent anti-tumour activity in colon and breast cancer models, and the ‘272 patent relates…

    By Donald Zuhn — On Tuesday Oncolytics Biotech Inc. announced that it had been granted U.S. Patent No. 7,252,817.  The ‘817 patent, which relates to methods for treating cell proliferative disorders such as neoplasms by administering modified modified herpes simplex viruses (HSV) to proliferating cells having an activated Ras-pathway, was the twenty-second U.S.…

    By Donald Zuhn — Rosetta Genomics, Ltd. announced on July 31, 2007 that it had been granted U.S. Patent No. 7,250,496.  While the ‘496 patent discloses two large groups of genes: 20,600 genomic address messenger (GAM) genes, which selectively inhibit the translation of disease-associated target genes, and 6,635 genomic record (GR) genes –…